disease-free survival


Also found in: Acronyms.
The amount of time that a person with a disease—usually understood to mean cancer—lives without known recurrence. Disease-free survival is a major clinical parameter used to evaluate the efficacy of a particular therapy, which is usually measured in ‘units’ of 1 or 5 years

disease-free survival

Oncology The time that a person with a disease lives without known recurrence; DFS is major clinical parameter used to evaluate the efficacy of a particular therapy, which is usually measured in 'units' of 1 or 5 yrs. See Cure, Remission.
References in periodicals archive ?
The combination of a single HDR treatment and a short course of EBRT can result in a biochemical disease-free survival of over 95% (Table 2), with a low rate of late toxicity.
The 5-year pelvic disease-free survival rate for the group as a whole was 76%.
Disease-free survival was significantly better in vaccinated patients who expressed two or more of the five prospectively defined HLA alleles (p=0.
For 4 years, that panel has lent its considerable influence to the early, aggressive use of antiretroviral therapy in patients who have relatively high CD4 T cell counts, even as evidence supporting the long-term clinical benefit of that practice has remained lacking, and even as observational data have shown that early therapy offers no disease-free survival benefit.
The impact of tumor size, mitotic count, lymphovascular invasion, tumor grade, and S-phase fraction on disease-free survival times in pN0 patients is well documented.
That would have given Medlen a 50 to 70 percent chance of long-term, disease-free survival.
On the basis of current trends, the two groups have similar projections of disease-free survival.
The data show that 38% of newly diagnosed patients who received ICT-107 continue to show no tumor recurrence after three years, compared to the historic disease-free survival rate of 6% with SOC.
9, 2013 /PRNewswire/ -- The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML).
SAN ANTONIO -- In sharp contrast with previous findings, zoledronic acid failed to improve disease-free survival when added to adjuvant chemotherapy for women with stage II/III breast cancer in a highly anticipated phase III trial.
Scientifics evaluated those criteria: disease-free survival, global survival, treatment security levels and life quality.